CORE--HUMAN TUMOR CLONING ASSAY (HTCA)

实验室核心9004的中心焦点是应用体外人类 肿瘤克隆形成试验(HTCA)辅助抗癌新药开发 由本项目中的实验室和临床项目调查人员 项目以及与临床试验的相关性。HTCA研究的药物 包括细胞毒剂、化疗增敏剂生长因子、生长因子 拮抗剂和其他生物制品。HTCA主要使用Fresh进行 从活检标本中获取人类肿瘤的信息 体内与新药开发和药物援助的潜在相关性 选择进入临床试验并确定可取的 第一阶段要达到的给药时间表和血浆浓度 临床试验。此外，hTCA可能有助于肿瘤的识别。 招募进入第二阶段试验的类型和特定药物敏感性 测试的特定新制剂的数量。开展了其他相关研究。 已建立的人类肿瘤细胞系也用于高质量 HTCA标准化控制。因此，该实验室的核心资源 支持所有项目调查人员的研究活动 计划项目。

The central focus of laboratory core 9004 is to apply the in vitro Human Tumor Clonogenic Assay (HTCA) to aid in new anticancer drug development by the laboratory and clinical project investigators in this program project and for correlation with clinical trials. Drugs studied in HTCA include cytotoxic agents, chemosensitizers growth factors, growth factor antagonists and other biologics. HTCA is conducted primarily with fresh human tumors from biopsy specimens in order to gain information of potential in vivo relevance to new drug development, and to aid in drug selection for advancement to clinical trials and to identify desirable dosing schedules and plasma concentrations to be achieved in phase I clinical trials. Additionally, HTCA may aid in identification of tumor types and specific drug sensitive for recruitment into phase II trials of specific new agents tested. Other related studies are carried out with established human tumor cell lines which are also used in quality control for standardization of HTCA. Thus this laboratory core resource supports research activities of all projects investigators in this program project.